Endometrial cancer is preceded by endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations, but the precise causes of endometrial cancer remain uncertain. Mig-6, mainly known as a negative regulator of the EGF receptor, is an important mediator of progesterone signaling in the uterus, where it mediates tumor suppression by modulating endometrial stromal-epithelial communications.
Introduction
Endometrial carcinoma, commonly referred to as uterine cancer, is the most common malignancy of the female genital tract. In the United States, approximately 49,560 cases are diagnosed and approximately 8, 190 women die from the disease each year (1) . The most common type of endometrial carcinoma, approximately 85% of cases, is endometrioid carcinoma (2) . Endometrial hyperplasia, which is a proliferative process in the epithelium, is associated with endometrioid carcinoma. This process is commonly associated with unopposed estrogen stimulation (3) .
The ability of ovarian steroids to regulate uterine cell proliferation depends upon the ability of hormonal stimulation to regulate growth factor communication networks between the uterine stroma and epithelium. E 2 stimulates proliferation of uterine epithelial cells while P 4 is inhibitory to estrogen-mediated proliferation of the epithelium. P 4 achieves this inhibition of proliferation by coordinating stromal-epithelial crosstalk (4) (5) (6) . Elucidating the molecular mechanisms by which the steroid hormones control uterine physiology is paramount to understanding female infertility and tumorigenesis of endometrial cancer.
Progestin therapy has been used in the conservative endocrine treatment of endometrial complex atypical hyperplasiathe direct precursor lesion to endometrial cancer in women in order to preserve their fertility-as well as in palliative treatment to advanced-stage patients who are poor surgical candidates (7) (8) (9) . Expression of PR has been positively correlated with good prognosis and response to progestin treatment (10) . However, more than 30% of patients do not respond to progestin due to de novo or acquired progestin resistance (8, (11) (12) (13) (14) . The mechanism of progestin resistance is still unknown.
Mitogen inducible gene 6, Mig-6 (Errfi1, RALT, or gene 33), is an immediate early-response gene that can be induced by various mitogens and commonly occurring chronic stress stimuli. It contains a CRIB domain, a src homology 3 (SH3) binding domain, a 14-3-3 binding domain, and an EGF receptor-binding domain as an adaptor protein, but no domain with enzymatic activity (15) . Ablation of Mig-6 in mice has led to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinomas in organs such as the uterus, lung, gallbladder, and bile duct (16) (17) (18) . We identified Mig-6 as a target of progesterone receptor (PR) action using a genomewide gene expression profiling (19, 20) , and showed that targeted ablation of Mig-6 gene in the mouse uterus led to the development of endometrial hyperplasia and estrogeninduced endometrial carcinoma (18, 20) . Using this mouse model, we further showed that Mig-6 suppresses estrogen signaling in the presence of progesterone and that Mig-6 regulates PTEN-phosphoinositide 3-kinase (PI3K)-AKT signaling (21) . In searching for relevance of the findings from the animal study to human endometrial cancer, we found a significantly lower MIG-6 expression in human endometrioid carcinoma cells compared with normal uterine cells, suggesting a similar Mig-6-regulated system present in the human uterus (20) . Tumor suppressor function of Mig-6 coordinates endometrial stromal-epithelial communication. The expression of Mig-6 in these cellular compartments is under tight temporal and endocrine control. However, the function of Mig-6 in endometrial cancer has remained elusive.
In this study, we used endometrial epithelial-cell-specific Mig-6 knockout (Wnt7a creþ Mig-6 f/f ) mice to assess the role of epithelial Mig-6 in steroid hormone responsiveness and tumorigenesis (18, 22) . We observed that Wnt7a creþ f/f mice display normal P 4 attenuation of E 2 -mediated uterine hypertrophy. However, Wnt7a creþ Mig-6 f/f mice develop endometrial hyperplasia as well as estrogen-induced endometrial cancer. The development of endometrial hyperplasia in Wnt7a creþ f/f mice is prevented by P 4 treatment. These data suggest that P 4 -induced stromal Mig-6 prevents hyperplasia seen in Wnt7a creþ f/f mice by regulating estrogen signaling.
Materials and Methods

Animals and tissue collection
Mice were cared for and used in the designated animal care facility according to the Michigan State University institutional guidelines. All animal procedures were approved by the Institutional Animal Care and Use Committee of Michigan State University. We generated uterine epithelial-specific Mig-6 knockout mice using the Wnt7a-cre mouse model (23, 24) . Control mice and Wnt7a creþ Mig-6 f/f mice were ovariectomized at 6 weeks of age. Two weeks later, ovariectomized control and Wnt7a creþ f/f mice were injected with one of the following: vehicle (sesame oil), P 4 (1 mg/mouse), E 2 (0.1 mg/mouse), and P 4 plus E 2 . Five mice from each group were injected with one of these treatments every 24 hours and uteri were collected at 72 hours. For the determination of the development of endometrial hyperplasia and estrogen/progesterone effects, either vehicle (beeswax), E 2 (20 mg/pellet), or P 4 (40 mg/pellet) pellets were placed subcutaneously into ovariectomized control and Wnt7a creþ Mig-6 f/f mice for every 1 month and aged for 3 months before euthanization. Uterine tissues were flash-frozen at the time of dissection and stored at À80 C for RNA isolation or fixed with 4% (vol/vol) paraformaldehyde for histologic analysis.
Quantitative real-time PCR
RNA was extracted from the uterine tissues using the RNeasy total RNA isolation kit (Qiagen). Expression levels of mRNA transcripts for Mig-6, estrogen receptor a (ERa) target genes (Muc-1, Clca3, Ltf, Birc1a, and Birc1b), PR target genes (Mig-6, Fst, and Il13ra2), and 18S rRNA (for normalization) were measured by quantitative real-time PCR (qRT-PCR) analysis using the Applied Biosystems StepOnePlus qRT-PCR systems according to the manufacturer's instructions (PE Applied Biosystems). Prevalidated TaqMan probes and primers were purchased from Applied Biosystems. cDNA was produced from 1 mg of total RNA using random hexamers and MMLV Reverse Transcriptase (Invitrogen Corp.). RT-PCR was carried out using RT-PCR Universal Master Mix reagent (Applied Biosystems) according to the manufacturer's instructions. All RT-PCR was done by using five independent RNA sets. The relative expression of each transcript was normalized to 18S rRNA using ABI rRNA control reagents. Statistical analyses were conducted using Student t test and one-way ANOVA. Differences between multiple groups were determined by Tukey post hoc multiple comparisons test. Statistical analyses were conducted using the Instat package from GraphPad.
Immunohistochemistry
Uterine sections from paraffin-embedded tissue were cut at 5 mm and mounted on silane-coated slides, deparaffinized, and rehydrated in a graded alcohol series. Sections were preincubated with 10% normal goat serum in PBS (pH 7.5) and then incubated with primary antibody diluted in 10% normal goat serum in PBS (pH 7.5) overnight at 4 C at the following dilutions: 1:200 for anti-PR antibody (sc-7208, Santa Cruz Biotechnology), 1:500 for anti-ERa (M-7047, DAKO Corp.), 1:50 for anti-MIG-6 (PE-16, Sigma), 1:1,000 for antiphosphohistone H3 (06-570, Millipore), 1:500 for anti-cleaved caspase 3 (cat. no. 9661, Cell Signaling Technology), 1:200 for anti-NOTCH1 (sc-6014-R, Santa Cruz Biotechnology), 1:200 for anti-BIRC3 (ab32059, Abcam Inc.), 1:1,000 for anti-STAT3 (cat. no. 4904, Cell Signaling Technology), 1:100 for anti-phospho-STAT3 (cat. no. 9131, Cell Signaling Technology). On the following day, sections were washed in PBS and incubated with a secondary antibody (5 ml/mL; Vector Laboratories) for 1 hour at room temperature. Immunoreactivity was detected using the Vectastain Elite DAB kit (Vector Laboratories).
Isolation of the uterine epithelium
Isolated uteri were placed into Hanks balanced salt solution (HBSS; Ca 2þ -free and Mg 2þ free), and cut into 1-mm segments. The cut uteri were placed into 1% trypsin/HBSS solution for 1.5 hours at room temperature and then washed with cold HBSS. The uteri were placed into 20% FBS/HBSS solution for 5 minutes, and washed with cold HBSS. The uteri were then incubated with DNase I solution for 1 minute to breakdown DNA. The uterine luminal epithelium was gently removed from the uterine stroma under a dissecting microscope.
Results
Generation of epithelial Mig-6 ablation in the murine uterus Previously, we generated conditional ablation of Mig-6 in all compartments of the uterus (PR cre/þ Mig-6 f/f ), which leads to the development of endometrial hyperplasia and estrogeninduced endometrial cancer (18, 20) . Mig-6 is a critical mediator of stromal-epithelial communication in steroid hormone regulation and tumor suppressor function. In order to investigate the role of epithelial Mig-6 in the uterus, we bred Mig-6 f/f mice to Wnt7a-Cre mice (22) (23) (24) (Fig. 1A) . In control mice, MIG-6 was expressed in the luminal epithelium, glandular epithelium, and stroma. However, MIG-6 was only detected in stroma but not the epithelial cells of Wnt7a creþ Mig-6 f/f mice (Fig. 1B) . These results suggested that we successfully generated epithelial Mig-6 ablation in the uterus of mice.
Steroid hormone regulation and tumor suppressor function of epithelial Mig-6
We showed that PR cre/þ Mig-6 f/f mice result in the inability of P 4 to inhibit E 2 -induced uterine weight gain and expression of E 2 -responsive target genes (20) . To examine the effect of ovarian steroid hormone regulation on epithelial Mig-6 expression, ovariectomized control and Wnt7a creþ f/f mice were injected daily with either vehicle (sesame oil), P 4 , E 2 , and E 2 þ P 4 for 3 days (n ¼ 5 per genotype per treatment). Wnt7a creþ Mig-6 f/f mice displayed a normal P 4 attenuation of E 2 -mediated uterine hypertrophy ( Supplementary Fig. S1 ). These results suggest that stromal Mig-6 has an important role in acute steroid hormone responsiveness. PR cre/þ Mig-6 f/f mice developed endometrial hyperplasia and cancer in a hormone-dependent manner (20) . We examined the development of endometrial hyperplasia and steroid hormone-dependent endometrial cancer in the Wnt7a creþ Mig-6 f/f mice. To investigate the impact of epithelial Mig-6 ablation on endometrial hyperplasia development, control and Wnt7a creþ Mig-6 f/f mice were sacrificed at 5 months of age. Uterine weight as well as gross and histologic morphology were examined (n ¼ 5 per genotype). Wnt7a creþ Mig-6 f/f mice showed an increased gross morphology when compared with control mice (Fig. 1C) . Uterine weight was significantly increased in Wnt7a creþ Mig-6 f/f mice when compared with control mice (Fig.  1D ). Histologic analysis revealed that Wnt7a creþ f/f mice developed endometrial hyperplasia (Fig. 1E ). In addition, Wnt7a creþ Mig-6 f/f mice developed estrogen-dependent endometrial cancer ( Supplementary Fig. S2 ). To address whether endometrial hyperplasia in Wnt7a creþ f/f mice is caused by an alteration in endometrial epithelial cell proliferation, we conducted immunohistochemical analysis for phosphohistone H3, a mitotic marker, in endometrium from mice at 3 and 5 months of age. The levels of phosphohistone H3 were significantly increased in epithelial cells of Wnt7a compared with controls at both 3 and 5 months of age ( Fig. 2A and B) . However, proliferation in stromal cells of Wnt7a creþ Mig-6 f/f mice was not changed. Notch pathway activation leads to increased proliferation and tumor progression in endometrial cancers (25) . Because ablation of Notch1 in PRpositive cells showed decreased cellular proliferation (26), we examined NOTCH1 expression in highly proliferative epithelial cells of Wnt7a creþ Mig-6 f/f mice. Wnt7a creþ Mig-6 f/f uteri showed a robust expression of NOTCH1 in the luminal and glandular epithelium, while the Mig-6 f/f mice display NOTCH1 expression only in the stroma (Fig. 2C) .
The number of cleaved caspase-3-positive cells was significantly increased in epithelial cells of Wnt7a creþ Mig-6 f/f mice compared with controls. Interestingly, apoptosis in subepithelial stromal cells of Wnt7a creþ Mig-6 f/f mice was significantly increased compared with control mice at 3 and 5 months of age ( Fig. 2D and 2E ). BIRC3 contributes to the survival of endometrial cancer cells against apoptosis mediated by inhibition of AKT (27) . Therefore, it was determined whether Wnt7a creþ f/f mice altered regulation of BIRC3 during endometrial hyperplasia development. The expression of BIRC3 was increased in the luminal and glandular epithelium of Wnt7a creþ Mig-6 f/f mice compared with Mig-6 f/f mice, whereas it was not observed in the subepithelial stromal cells of Wnt7a creþ f/f mice (Fig. 2F) . Expression of PR has been reported as a prognostic factor for endometrial carcinoma (28) (29) (30) . We evaluated the expression of PR by immunohistochemistry in mice at 3 and 5 months of age. Immunostaining of PR showed a significant decrease of stromal PR expression in the endometrium of Wnt7a creþ f/f mice when compared with control mice at 5 months of age ( Fig. 3A  and B) . These results indicate that Wnt7a creþ Mig-6 f/f mice exhibited development and progression of endometrial cancer as observed in humans. Activation of STAT3 interacts with PR for decidualization in the uterus. The expression of stromal PR was decreased during decidualization and the preimplantation period in PR cre/þ Stat3 f/f mice and PR target genes were significantly downregulated after progesterone treatment (31) . Therefore, we examined the expression of STAT3 by immunohistochemistry in endometrial hyperplasia from Wnt7a creþ Mig-6 f/f mice at 3 and 5 months of age. The immunostaining results showed decreased STAT3 protein in endometrial stroma of Wnt7a creþ Mig-6 f/f mice when compared with control mice at 3 and 5 months of age (Fig. 3C) .
Prevention of the development of endometrial hyperplasia by progesterone treatment P 4 has been used as a therapeutic agent for the treatment of early-stage endometrial cancer in patients (11) . However, the effectiveness of P 4 for women with endometrial cancer is less clear. To assess the effect of P 4 on epithelial ablation of Mig-6, we placed P 4 or vehicle pellets subcutaneously into the control, PR cre/þ Mig-6 f/f , and Wnt7a creþ Mig-6 f/f mice at 6 weeks of age and treated for 3 months (n ¼ 8 per genotype per treatment). There was no reduction in the development of endometrial hyperplasia with P 4 treatment in the PR cre/þ Mig-6 f/f mice. However, the development of endometrial hyperplasia in the Wnt7a creþ Mig-6 f/f mice was prevented by P 4 treatment (Fig.  4A) .
To determine whether the prevention of endometrial hyperplasia in Wnt7a creþ f/f mice was caused by an alteration in cell proliferation and apoptosis, we examined the immunohistochemical samples for phosphohistone H3 and cleaved caspase 3 following P 4 treatment. Immunostaining of phosphohistone H3 showed a significant decreased expression in the endometrial epithelium of Wnt7a creþ Mig-6 f/f mice compared with PR cre/þ Mig-6 f/f mice after P 4 treatment ( Fig. 4B  and C Mig-6 f/f mice ( Fig. 4B and D) . In addition, apoptosis of stromal cells was not observed in Wnt7a creþ f/f mice after P 4 treatment. These results suggest that activation of P 4 signaling including Mig-6 in stroma induces epithelial cell apoptosis.
To determine whether the suppression of the hyperplastic phenotype observed was due to altered ovarian steroid hormone signaling, we examined the expression of ERa and PR using immunohistochemisty. The expression of ERa was significantly decreased in the endometrium of Wnt7a creþ Mig-6 f/f mice as compared with control and PR cre/þ Mig-6 f/f mice after P 4 treatment (Fig. 5A ). Transcript levels of the ERa target genes, Muc-1, Clca3, and Ltf, were also significantly decreased in the Wnt7a creþ Mig-6 f/f mice as compared with the PR cre/þ Mig-6 f/f mice after P 4 treatment (Fig. 5B) . It is known that E 2 can tip this balance toward cell survival in uterine epithelial cells by inducing the expression of baculoviral inhibitors of apoptosis repeat-containing 1 (Birc1), a family of antiapoptotic proteins (32) . To determine if P 4 treatment suppresses uterine epithelial apoptosis by suppressing Birc1 expression, the expression of Birc1a and Birc1b was determined in control, PR cre/þ Mig-6 f/f , and Wnt7a creþ Mig-6 f/f mice treated with P 4 for 3 months by realtime RT-PCR. Interestingly, the expression of Birc1a and Birc1b was significantly decreased in the Wnt7a creþ Mig-6 f/f mice as compared with the PR cre/þ Mig-6 f/f after P 4 treatment (Fig. 5B) . These results suggest that P 4 treatment induces uterine epithelial apoptosis via downregulation of Birc1 expression.
The expression of PR was not significantly different between control and Wnt7a creþ Mig-6 f/f mice after P 4 treatment. However, transcript levels of the PR target genes Mig-6, Fst, and Il13ra2 were increased in the Wnt7a Mig-6 f/f mice after P 4 treatment (Fig. 6) . Therefore, BIRC3 and NOTCH1 may play an important role in the development of hyperplasia in Wnt7a creþ f/f mice. These results suggest that activated stromal P 4 signaling including Mig-6 prevents the development of endometrial epithelial hyperplasia seen in the Wnt7a creþ Mig-6 f/f mice by regulating estrogen signaling. Discussion P 4 and E 2 , acting through their cognate nuclear receptors, play critical roles in uterine functions associated with the establishment and maintenance of pregnancy (33, 34) . E 2 is required for proliferation and differentiation of the uterine epithelium whereas the coordinated action of E 2 and P 4 promotes stromal cell differentiation (35) . Elucidating P 4 -regulated pathways in the uterus is thus critical for understanding the impairments that underlie disruption of steroid hormone control of uterine cell proliferation and differentiation. The progesterone-induced gene Mig-6 suppresses E 2 signaling as a tumor suppressor by regulating proliferation and apoptosis in endometrial cancer (20, 21) . The expression of Mig-6 in these cellular compartments is under tight temporal and endocrine control (15) . However, the in vivo role of Mig-6 in uterine epithelium has remained elusive.
To understand the role of epithelial Mig-6 in the uterus, we generated ablation of uterine epithelial Mig-6 using Wnt7aCre mice (Fig. 1) . Ablation of epithelial Mig-6 in the murine uterus did not show any alterations in ovarian morphology, ovulation, or fertilization. In addition, there were normal levels of P 4 and E 2 in the serum of Wnt7a creþ f/f mice (data not shown). One of the endocrine risk factors for developing endometrial cancer and endometriosis is exposure to E 2 ; conversely, a lower incidence of these diseases in women is associated with decreased endogenous E 2 production (36). Although Wnt7a creþ Mig-6 f/f mice have normal acute steroid hormone responsiveness ( Supplementary Fig. S1 ), Wnt7a creþ Mig-6 f/f mice developed endometrial hyperplasia (Fig. 1) . Endometrial hyperplasia is defined as an increased proliferation of the endometrial glands relative to the stroma, resulting in an increased gland-to-stroma ratio when compared with normal proliferative endometrium (37) . Endometrial hyperplasia deserves special attention because of its relationship with endometrial carcinoma. Clinicopathologic and epidemiologic studies have supported the malignant potential of endometrial hyperplasia and the concept of a continuum of proliferative glandular lesions culminating, in some cases, in carcinoma. However, details of molecular signaling during development of endometrial hyperplasia have remained elusive. Our mouse models are invaluable for further study of endometrial tumorigenesis.
Proliferation in epithelial cells and apoptosis in subepithelial stromal cells were significantly increased in Wnt7a creþ f/f mice compared with control mice in epithelial cells at 5 months of age (Fig. 2) . These results indicate that these increases lead to the development of endometrial hyperplasia. Notch signaling plays an important role in the regulation of cellular proliferation, differentiation, and apoptosis (38) . Deregulation of Notch signaling was found in a variety of cancers (38) . Moreover, Notch signaling is prominently regulated by estrogen (39, 40) . Here, it is shown that epithelial Mig-6 inhibits epithelial proliferation through its regulation of NOTCH1 protein (Fig. 2C) . The inhibitor of apoptosis proteins (IAP) are negative key regulators of apoptosis (41) . Alterations in IAPs are found in many types of human cancer and are connected with chemoresistance, disease progression, and poor prognosis (42, 43) . IAPs have important roles in suppression of estrogen-mediated apoptosis in the uterine epithelium (32) . Because the cellular inhibitor of apoptosis genes including Birc1 and Birc3 can tip toward cell survival in uterine epithelial cells (27, 32) . The expression of Birc1 and Birc3 was significantly increased in Wnt7a Mig-6 f/f mice leads to the development of endometrial hyperplasia through BIRC3 and NOTCH1. The mechanism by which this is achieved is suggested to be through the EGFR-ERK and PI3K-AKT signaling pathways (27) . Therefore, future studies are needed to determine whether it is through these pathways or others that epithelial Mig-6 regulates proliferation and apoptosis.
As P 4 attenuates E 2 regulation of proliferation and gene expression by regulating the expression of a yet-to-be-identified paracrine signal from the stromal to the epithelial cells, the regulation of the expression of PR in the endometrial stromal cells by epithelial Mig-6 is critical for the ability of P 4 to attenuate the E 2 -regulated proliferation, apoptosis and expression of ERa target genes. Wnt7a creþ f/f mice exhibited reduced PR expression in stromal cells (Fig. 3) , as observed in human endometrial cancer (30, 44) . It has been reported that PR is essential for uterine biology as a key regulator of uterine epithelial-stromal crosstalk (45, 46) . P 4 was unable to stimulate the expression of its epithelial target genes and inhibit neonatal endometrial glandular development in conditional ablation of epithelial PR in the uterus of Wnt7a creþ PR f/-mice (24) . PR directly interacts with STAT3 through protein-protein interactions (31, 47) . STAT3 signaling pathways are activated by cytokines and growth factors. The expression of stromal PR was decreased during decidualization and the preimplantation period in PR cre/þ Stat f/f mice, and PR target genes were significantly downregulated after progesterone induction (31) . The expression of PR and STAT3 was decreased during the development of endometrial hyperplasia in the stroma of Wnt7a creþ Mig-6 f/f mice (Fig. 3) . There are differential roles in uterine stromal and epithelial compartments, and stromalepithelial communication is critical in pregnancy, steroid hormone regulation, and in tumor suppressor function. Therefore, these results suggest that dysregulation of STAT3 and PR crosstalk is important for endometrial hyperplasia development.
In contrast, a negative risk factor for these endometrial diseases is exposure to P 4 (48) . It is well known that endometrial cancer is an estrogen-dependent disease and progestin therapy has been used successfully to slow the growth of endometrial tumors in women who are poor surgical candidates as well as to reverse endometrial complex atypical hyperplasia in women who wish to retain their fertility (5) (6) (7) (8) . The mechanism by which progestins slow the growth of endometrial cancer cell is due to their inhibitory effects on E 2 action (49 f/f mice in epithelial cells after P 4 treatment. It is known that baculoviral inhibitors of apoptosis repeat-containing 1 (Birc1), a family of antiapoptotic proteins as functional targets of estrogen through its receptor, can suppress uterine epithelial cells (32) . To determine if stromal Mig-6 activated by P 4 promotes uterine epithelial apoptosis by suppressing Birc1 expression, we determined transcription levels of Birc1a and Birc1b. These genes were significantly decreased in Wnt7a creþ Mig-6 f/f mice compared with PR cre/þ Mig-6 f/f mice after P 4 treatment (Fig. 5) . Levels of ERa protein and ERa target genes (Muc-1, Clca3, and Ltf) were decreased in Wnt7a creþ Mig-6 f/f compared with PR cre/þ Mig-6 f/f mice after P 4 treatment (Fig. 5) . The PR protein level was not changed between PR cre/þ Mig-6 f/f and Wnt7a creþ Mig-6 f/f mice. However, expression of PR target genes, Mig-6, Fst, and Il13ra2 was highly increased in Wnt7a creþ Mig-6 f/f compared with PR cre/þ Mig-6 f/f mice after P 4 treatment ( Supplementary Fig.  S3 ). BIRC3 is induced by progestins through PRB and contributes to the survival of endometrial cancer cells against apoptosis mediated by inhibition of AKT (27) . The levels of BIRC3 were decreased in Wnt7a creþ f/f mice while the high levels of BIRC3 were not altered in PR creþ Mig-6 f/f mice after P 4 treatment (Fig. 6) . It suggested that the induction of BIRC3 by P 4 plays a role in the resistance to P 4 therapy observed in some women with endometrial carcinoma (27) . Our results support the function of BIRC3 in the resistance of P 4 therapy. It is sufficient to function as a tumor suppressor and/or mediator of PR-P 4 signaling, although expression of Mig-6 in Wnt7a creþ Mig-6 f/f mice is lower than control mice after P 4 treatment. Our results suggest that activated stromal Mig-6 can regulate proliferation and apoptosis via regulation of ERa activity in the epithelium, can contribute to the prevention of endometrial hyperplasia, and that epithelial Mig-6 is a critical tumor suppressor involved in P 4 -mediated protection against the development of endometrial cancer. These results suggest that epithelial Mig-6 is critical for a tumor suppressor function in endometrial cancer.
In conclusion, our results show the role of epithelial Mig-6 in steroid hormone regulation and endometrial cancer. Ablation of epithelial Mig-6 in the murine uterus resulted in development of endometrial hyperplasia and P 4 treatment prevented the occurrence of the endometrial hyperplastic phenotype, which occurs via Mig-6 regulation of ERa activity ( Table 1) . The Wnt7a creþ f/f model is useful for studying new targets during cancer progression and can be exploited therapeutically to identify new therapies for the prevention and treatment of endometrial cancer. Determining the role of Mig-6 in stromalepithelial crosstalk will be critical in understanding the role of steroid hormone signaling in endometrial function and dysfunction associated with infertility and endometriosis as well as in developing therapy for both of these common uterine diseases.
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